Business
H.C. Wainwright Global Investment Conference
H.C. Wainwright Global Investment Conference.
About this update from Poolbeg Pharma Plc
[{"type":"text","content":"\n\nPoolbeg Pharma plc\n \nPoolbeg Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference\n \n27 August 2024 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that Jeremy Skillington, PhD, Chief Executive Officer and David Allmond, Chief Business Officer will present virtually at the H.C. Wainwright 26th Annual Global Investment Conference, being held on 9-11 September 2024 in New York and virtually.\nThe presentation will be available to view on demand from 12pm BST / 7am ET on Monday 9 September 2024. \nIn addition to the presentation, management will be available at the conference in New York for in-person one-on-one meetings with investors on 9-11 September. To schedule a meeting, investors should contact their H.C. Wainwright representative or contact Poolbeg directly at [email protected].\nEnquiries \n \n\n\n\n\nPoolbeg Pharma Plc \nJeremy Skillington, CEO \nIan O'Connell, CFO \n \n\n\n+44 (0) 207 183 1499 \n\n\n\n\nCavendish Capital Markets Ltd (Nominated Adviser & Joint Broker) \nGeoff Nash, Camilla Hume (Corporate Finance)\nNigel Birks, Harriet Ward (ECM) \n \n\n\n+44 (0) 207 220 0500 \n\n\n\n\nShore Capital Stockbrokers Ltd (Joint Broker)\nDavid Coaten, Harry Davies-Ball (Corporate Advisory), Malachy McEntyre, Isobel Jones (Corporate Broking)\n \n\n\n+44 (0) 207 408 4090\n\n\n\n\nJ&E Davy (Joint Broker) \nAnthony Farrell, Niall Gilchrist \n \n\n\n+353 (0) 1 679 6363 \n\n\n\n\nOptimum Strategic Communications \nNick Bastin, Vici Rabbetts, Elena Bates \n \n\n\n+44 (0) 208 078 4357 \[email protected] \n\n\n\n\n\n\n\n\n\n \nAbout Poolbeg Pharma \n \nPoolbeg Pharma plc is committed to the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, with a growing emphasis on rare and orphan diseases. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative produ...